<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7060">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960206</url>
  </required_header>
  <id_info>
    <org_study_id>33/45</org_study_id>
    <nct_id>NCT00960206</nct_id>
  </id_info>
  <brief_title>ABC/Trident® Ceramic Post Approval Study</brief_title>
  <official_title>Post-Approval Study of the ABC and Trident® Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Orthopaedics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Post Approval Study of the ABC and Trident® systems is to continue to
      demonstrate the safety and efficacy of the alumina-on-alumina bearing surfaces combined with
      the appropriate shell in a cementless application.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ABC/ Trident® study was initiated in 1996 as an FDA IDE pre-market study in the United
      States for alumina bearing THR. PreMarket Approval (PMA)application was approved in February
      3,2003. The Post Approval Study (PAS) involved six surgeon investigators from the original
      IDE study. Subjects who consented to participate in the Post Approval Study continued to be
      followed to collect limited patient reported data regarding status of the hip.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Component Revision and Complications</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of hips in which the study device was removed and replaced with a new component/s is listed. Complications (adverse events) are listed in the adverse event section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>3-5 and 10 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.
90 - 100 = excellent
80 - 89 = good
70 - 79 = fair
0 - 69 = poor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Evaluation</measure>
    <time_frame>3-5 and 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Failure is defined as progressive femoral radiolucency (RLL) &gt; or = 2mm around entire stem, progressive subsidence &gt; or = 5mm, progressive acetabular radiolucency (RLL) &gt; or = 2 mm around entire cup, or cup migration &gt; or = 3mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Follow-Up Questionnaire</measure>
    <time_frame>6-10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>A three question follow-up questionnaire was administered annually asking whether the participant is satisfied with the study total hip replacement(THR) (noted as &quot;satisfied&quot; below); whether they have any study hip pain (noted as &quot;no pain&quot; below); and whether they have had any surgery on the study hip during the previous year noted as &quot;no surgery&quot; below).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">413</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <arm_group>
    <arm_group_label>Trident®System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trident® Ceramic Insert/Trident® AD HA Acetabular Shell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABC System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trident® Ceramic Insert/Trident® AD HA Acetabular Shell</intervention_name>
    <description>Trident® Ceramic Insert/Trident® AD HA Acetabular Shell</description>
    <arm_group_label>Trident®System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell</intervention_name>
    <description>Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell</description>
    <arm_group_label>ABC System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell</intervention_name>
    <description>OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The individual has signed a Patient Informed Consent (PIC), specific to this study,
             and approved by the Institutional Review Board (IRB).

          -  The individual is between the ages of 21 and 75 years.

          -  The individual is not classified as morbidly obese.

          -  The individual clinically qualifies for total hip arthroplastic surgery based on
             physical examination and medical history.

          -  The individual is diagnosed with a primary diagnosis of Non-Inflammatory Degenerative
             Joint Disease (osteoarthritis, traumatic arthritis, avascular necrosis, slipped
             capital epiphysis, pelvic fracture, femoral fracture, failed fracture fixation or
             diastrophic variant).

          -  The individual does not have an active infection within the affected hip joint.

          -  The individual has not had a previous total hip replacement or hip fusion to the
             affected hip joint.

          -  The individual is physically and mentally willing and able to comply with
             postoperative scheduled clinical and radiographic evaluations and rehabilitation
             (i.e., not currently being treated for a psychiatric disorder, senile dementia,
             Alzheimer's disease, presence of alcohol or substance abuse).

          -  The individual does not have a neuromuscular or neurosensory deficiency that limits
             the ability to evaluate the safety and effectiveness of the device.

          -  The individual does not have a diagnosed systemic disease that would affect the
             subject's welfare or overall outcome of the study (i.e., moderate to severe
             osteoporosis, Paget's disease, renal osteodystrophy), is not immunologically
             suppressed, nor receiving steroids in excess of physiologic dose requirements.

          -  The individual is skeletally mature.

          -  The individual is not pregnant.

          -  The individual is not a prisoner.

          -  The individual has no plans to relocate to another geographic area before the
             completion of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Capello, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Bierbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Baptist Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D'Antonio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Greater Pittsburgh Orthopaedic Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Roberson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory Orthopaedics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Siverhus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toledo Joint Replacement and Orthopedic Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Zann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic Surgery Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic Surgery Associates</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univeristy</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Baptist Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Joint Replacement and Orthopedic Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Pittsburgh Orthopaedics Assoc.</name>
      <address>
        <city>Moon Township</city>
        <state>Pennsylvania</state>
        <zip>15108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 24, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2009</firstreceived_date>
  <firstreceived_results_date>June 7, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 413/464 participants/hips enrolled. Started, completed and not completed counts are reported by hip.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Trident® System</title>
          <description>Hip received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
        </group>
        <group group_id="P2">
          <title>ABC System</title>
          <description>Hip received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Hip received the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unwilling/Unable to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Revision of study component</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing 10 year data</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported by hip for each arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Trident System</title>
          <description>Trident Ceramic Insert/Trident AD with PureFix HA Shell</description>
        </group>
        <group group_id="B2">
          <title>ABC System</title>
          <description>Howmedica Osteonics Alumina Insert/either PSL Microstructured or Secur Fit HA PSL Shell</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Howmedica Osteonics Omnifit Series II Cup Inserts/Omnifit PSL Microstructured Shell</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="185"/>
                <measurement group_id="B3" value="89"/>
                <measurement group_id="B4" value="464"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>An approved protocol deviation allowed enrollment of a 12 y.o. female with juvenile RA.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.5" lower_limit="12" upper_limit="74"/>
                <measurement group_id="B2" value="53.9" lower_limit="26" upper_limit="75"/>
                <measurement group_id="B3" value="54.7" lower_limit="26" upper_limit="75"/>
                <measurement group_id="B4" value="53.08" lower_limit="12" upper_limit="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>hips</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
                <measurement group_id="B2" value="64"/>
                <measurement group_id="B3" value="35"/>
                <measurement group_id="B4" value="166"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="123"/>
                <measurement group_id="B2" value="121"/>
                <measurement group_id="B3" value="54"/>
                <measurement group_id="B4" value="298"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>hips</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="185"/>
                <measurement group_id="B3" value="89"/>
                <measurement group_id="B4" value="464"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Component Revision and Complications</title>
        <description>The number of hips in which the study device was removed and replaced with a new component/s is listed. Complications (adverse events) are listed in the adverse event section.</description>
        <time_frame>10 years</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Number of participants analyzed includes all subjects enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Trident® System</title>
            <description>Hip received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O2">
            <title>ABC System</title>
            <description>Hip received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Hip recevied the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of hips analyzed</title>
            <units>hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="185"/>
                  <measurement group_id="O3" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Component Revision and Complications</title>
            <description>The number of hips in which the study device was removed and replaced with a new component/s is listed. Complications (adverse events) are listed in the adverse event section.</description>
            <units>hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Harris Hip Score</title>
        <description>Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.
90 - 100 = excellent
80 - 89 = good
70 - 79 = fair
0 - 69 = poor</description>
        <time_frame>3-5 and 10 Years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants may have one or both hips replaced. Number of participants and hips analyzed include all enrolled. Number of hips with HHS evaluated at postoperative periods indicated is included in the outcome results posting.</population>
        <group_list>
          <group group_id="O1">
            <title>Trident® System</title>
            <description>Hip received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O2">
            <title>ABC System</title>
            <description>Hip received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Hip recevied the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hips analyzed</title>
            <units>Hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="185"/>
                  <measurement group_id="O3" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Harris Hip Score</title>
            <description>Scores can range from 0 to 100 with 0 being the worst and 100 being the best score. A score of 80-100 is considered good-excellent and a score less than or equal to 79 is considered fair-poor.
90 - 100 = excellent
80 - 89 = good
70 - 79 = fair
0 - 69 = poor</description>
            <units>hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 yr hips with good-excellent score (80-100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                  <measurement group_id="O2" value="171"/>
                  <measurement group_id="O3" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 yr hips with a fair-poor score (0-79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 yr hips with a good-excellent score (80-100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="148"/>
                  <measurement group_id="O2" value="164"/>
                  <measurement group_id="O3" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 yr hips with a fair-poor score (0-79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 yr hips with a good-excellent score (80-100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="158"/>
                  <measurement group_id="O3" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 yr hips with a fair-poor score (0-79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 yr hips with a good-excellent score (80-100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                  <measurement group_id="O2" value="115"/>
                  <measurement group_id="O3" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 yr hips with a fair-poor score (0-79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiographic Evaluation</title>
        <description>Failure is defined as progressive femoral radiolucency (RLL) &gt; or = 2mm around entire stem, progressive subsidence &gt; or = 5mm, progressive acetabular radiolucency (RLL) &gt; or = 2 mm around entire cup, or cup migration &gt; or = 3mm.</description>
        <time_frame>3-5 and 10 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants may have one or both hips replaced. Number of participants/hips analyzed includes all enrolled. Number of hips demonstrating radiographic failure assessment at postoperative periods indicated is included in the outcome results posting. Number of hips available for evaluation is indicated in the results heading by postoperative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Trident® System</title>
            <description>Hip received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O2">
            <title>ABC System</title>
            <description>Hip received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Hip recevied the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hips analyzed</title>
            <units>Hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="185"/>
                  <measurement group_id="O3" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Radiographic Evaluation</title>
            <description>Failure is defined as progressive femoral radiolucency (RLL) &gt; or = 2mm around entire stem, progressive subsidence &gt; or = 5mm, progressive acetabular radiolucency (RLL) &gt; or = 2 mm around entire cup, or cup migration &gt; or = 3mm.</description>
            <units>hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>3 yr failure (160 Trident®/174 ABC/82 Control)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 yr failure (153 Trident®/162 ABC/79 Control)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5 yr failure (128 Trident®/158 ABC/74 Control)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10 yr failure (60 Trident®/116 ABC/56 Control)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip Follow-Up Questionnaire</title>
        <description>A three question follow-up questionnaire was administered annually asking whether the participant is satisfied with the study total hip replacement(THR) (noted as &quot;satisfied&quot; below); whether they have any study hip pain (noted as &quot;no pain&quot; below); and whether they have had any surgery on the study hip during the previous year noted as &quot;no surgery&quot; below).</description>
        <time_frame>6-10 years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participants may have one or both hips replaced. Number of participants/hips analyzed includes all enrolled. Number of hips with positive three question responses at postoperative periods indicated is included in the outcome results posting. Number of hips available for evaluation is indicated in the results heading by postoperative period.</population>
        <group_list>
          <group group_id="O1">
            <title>Trident® System</title>
            <description>Hip received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O2">
            <title>ABC System</title>
            <description>Hip received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Hip recevied the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="166"/>
                  <measurement group_id="O3" value="87"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Hips analyzed</title>
            <units>Hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="185"/>
                  <measurement group_id="O3" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hip Follow-Up Questionnaire</title>
            <description>A three question follow-up questionnaire was administered annually asking whether the participant is satisfied with the study total hip replacement(THR) (noted as &quot;satisfied&quot; below); whether they have any study hip pain (noted as &quot;no pain&quot; below); and whether they have had any surgery on the study hip during the previous year noted as &quot;no surgery&quot; below).</description>
            <units>hips</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>6yr satisfied (Trident ®168/ABC 150/Control 79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="146"/>
                  <measurement group_id="O3" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6yr no pain (Trident ®168/ABC 150/Control 79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="129"/>
                  <measurement group_id="O3" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>6yr no surgery (Trident ®168/ABC 150/Control 79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7yr satisfied (Trident ®166/ABC 146/Control 71)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7 yr no pain (Trident ®166/ABC 146/Control 71)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                  <measurement group_id="O2" value="130"/>
                  <measurement group_id="O3" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>7 yr no surgery (Trident® 166/ABC 146/Control 71)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="165"/>
                  <measurement group_id="O2" value="145"/>
                  <measurement group_id="O3" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8yr satisfied (Trident ®164/ABC 141/Control 75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                  <measurement group_id="O2" value="141"/>
                  <measurement group_id="O3" value="73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8yr no pain (Trident ®164/ABC 141/Control 75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="140"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8yr no surgery (Trident ®164/ABC 141/Control 75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="164"/>
                  <measurement group_id="O2" value="141"/>
                  <measurement group_id="O3" value="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9yr satisfied (Trident ®150/ABC 162/Control 83)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="148"/>
                  <measurement group_id="O2" value="161"/>
                  <measurement group_id="O3" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9yr no pain (Trident ®150/ABC 162/Control 83)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="150"/>
                  <measurement group_id="O3" value="73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>9yr no surgery (Trident ®150/ABC 162/Control 83)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="162"/>
                  <measurement group_id="O3" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10yr satisfied (Trident ®143/ABC 148/Control 76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="142"/>
                  <measurement group_id="O2" value="148"/>
                  <measurement group_id="O3" value="76"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10yr no pain (Trident ®143/ABC 148/Control 76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="123"/>
                  <measurement group_id="O2" value="136"/>
                  <measurement group_id="O3" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10yr no surgery (Trident ®143/ABC 148/Control 76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="148"/>
                  <measurement group_id="O3" value="76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years</time_frame>
      <desc>Some participants were randomized to more than one hip system (17 participants/34 hips). Operative Site adverse events are reported by hip; systemic events are reported by participant. There were a total of 413 participants with 464 hips (190 Trident,185 ABC,89 Control) assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Trident® System</title>
          <description>Hips that received the Trident® Acetabular System with a ceramic insert and ceramic femoral head.</description>
        </group>
        <group group_id="E2">
          <title>ABC System</title>
          <description>Hips that received the ABC Acetabular System with a ceramic insert and ceramic femoral head.</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Hips that received the Omnifit Acetabular system with polyethylene insert and metal femoral head.</description>
        </group>
        <group group_id="E4">
          <title>All Participants</title>
          <description>All participants combined.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Non-operative Site Cardiac Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Operative Site Musculoskeletal and Connective Tissue Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="185"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="413"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Operative Site Musculoskeletal and Connective Tissue Disorder</sub_title>
                <counts group_id="E1" events="48" subjects_affected="36" subjects_at_risk="190"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="185"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI to publish results of this Clinical Study or the results of the activities hereunder, any abstract, manuscript, presentation or other communication shall be submitted to sponsor for review and approval at least 60 days prior to submission for publication. The sponsor retains the right to deny publication or, at its sole option, to revise the manuscript to delete proprietary or other confidential commercial information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research</name_or_title>
      <organization>Stryker Orthopaedics</organization>
      <phone>201-831-5401</phone>
      <email>Ellen.Axelson@stryker.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
